Whitechapel E1 Utilising our data driven approach to discovering emerging markets for Life Science, Lateral, in partnership with H.I.G. Capital, have acquired a prime site located in the heart of the emerging Whitechapel life science district, Med City. Situated next to Royal London Hospital, a leading, internationally renowned teaching hospital, the existing 50,000 sq ft building will be replaced with a landmark life science building in excess of 100,000 sq ft. Our partnership will be the first private development to deliver dedicated life science space in Whitechapel, a vision which has the support of government, Queen Mary University and Barts Health NHS Trust. Lateral have identified a further 1,000,000 sq ft that could be delivered, cementing Whitechapel as one of London’s only locations of targeted critical mass. Ongoing Case Study
Cambridge Cambridge is the UK’s most advance and mature life science market and part of the lauded Golden Triangle. Cambridge life science companies raised £9.7bn capital during 2021, a 411% increase from 2020 while being part of the top 10 global cities for VC raised (life science). Lateral are tracking over 1,000,000 sq ft of active laboratory demand in Cambridge with 2022-2023 stock levels close to zero. This led to the speculative acquisition of an office building in Cambridge to employ an intensive CapEx programme to deliver R&D laboratory space. Pre-completion Lateral secured a lease with leading life science company and were retained to deliver their fully fitted Global HQ. Ongoing
8
Made with FlippingBook - professional solution for displaying marketing and sales documents online